Canada markets close in 1 hour 43 minutes

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
27.24+0.56 (+2.10%)
As of 02:16PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close26.68
Bid27.39 x 1100
Ask27.51 x 800
Day's Range26.93 - 28.04
52 Week Range23.55 - 36.95
Avg. Volume572,472
Market Cap2.175B
Beta (5Y Monthly)1.58
PE Ratio (TTM)35.01
EPS (TTM)0.78
Earnings DateFeb. 21, 2022 - Feb. 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.25
  • GlobeNewswire

    Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

    SALT LAKE CITY, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will provide an update on the execution of the company’s strategic transformation and growth plans at the 40th Annual J.P. Morgan Health Care Conference at 2:15 p.m. ET on Jan. 11, 2022. Diaz will discuss the growing role of genetic insights in context with industry trends, new commercial capabilities and products that advance he

  • GlobeNewswire

    Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

    Nationwide search for permanent successor underwaySALT LAKE CITY, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the retirement of Jerry Lanchbury Ph.D. as chief scientific officer (CSO), after more than 19 years of distinguished service. A national search for a permanent CSO is underway. Lanchbury will provide consulting and scientific advisory services for Myriad Genetics through the end of the first

  • Zacks

    Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

    Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.